Feature | February 28, 2013

Medtronic Gains European Approval for Engager Transcatheter Valve

New Valve Provides Transapical Option for Physicians Treating Patients with Aortic Stenosis

Engager TAVI valve

 

February 28, 2013 — Medtronic Inc. announced European CE (Conformité Européenne) mark approval for its Engager Transcatheter Aortic Valve Implantation (TAVI) System with transapical delivery catheter. The system is indicated to treat patients with severe aortic stenosis who are at high or extreme risk for surgical aortic valve replacement (SAVR).

The new valve demonstrated positive clinical outcomes in its European Pivotal Trial. Results from the multi-center trial, which were presented during late-breaking trial sessions at the recent European Association for Cardio-Thoracic Surgery and the Society of Thoracic Surgeons annual meetings, revealed high rates of procedural success, minimal paravalvular leak (PVL) and continuing clinical benefits for patients over time.

In the trial, the Engager valve was delivered transapically and had 94.3 percent overall device success (according to Valve Academic Research Consortium modified definitions). There were no procedures requiring a second valve and no occurrences of valve embolization, coronary obstruction or device malposition. No patients had moderate or severe PVL at six months, as measured by an independent echocardiography core lab. In addition, while most patients (88 percent) were NYHA Class III or IV at baseline, at six months 82 percent of patients had improved to NYHA Class I or II.

“The Engager valve has demonstrated exceptional clinical results, and by adding it to our transcatheter valve portfolio, we are providing heart teams with more options for achieving the best outcomes for every patient with severe aortic stenosis,” said John Liddicoat, M.D., senior vice president of Medtronic and president of the Medtronic structural heart business.

The Medtronic Engager System is not available in the United States.

The Engager valve uses a minimally?invasive delivery system via a catheter inserted in the apex (the lower, pointed end) of the heart. The valve is comprised of bovine tissue leaflets and a self?expanding nitinol frame designed to promote annular sealing to minimize paravalvular leak. Control arms simplify implantation, and the supra-annular valve positioning facilitates leaflet coaptation (connections) in non-circular anatomy for optimal hemodynamic performance. A direct aortic delivery system for Engager will be introduced in the future.

For more information: www.medtronic.com

 

Related Content

sleep apnea, heart failure readmissions, Thomas Jefferson University study
News | Heart Failure| February 04, 2016
Early diagnosis and treatment of sleep apnea may reduce six-month readmissions for patients hospitalized with heart...
News | Heart Failure| February 04, 2016
New research from scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) published in the journal...
medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Technology | Information Technology| January 28, 2016
Boston Scientific Corp. and Accenture have developed a cloud-based, data-driven digital health solution for hospitals...
Sponsored Content | Case Study | Cardiovascular Ultrasound| January 21, 2016
This case study is from the Cardiac Imaging Department, Hospital Clinic, Barcelona, Spain.
pulmonary artery to left atrial shunt, heart lung transplant, Oswaldo, Stanford Children's Health

2015 was a year of dramatic changes for Oswaldo and his family, seen here at his bedside, post-transplant surgery in July. Photo courtesy of Business Wire.

Feature | Cardiovascular Surgery| January 15, 2016
2016 is starting off a whole lot better than last year for 14-year-old Oswaldo Jimenez of Salem, Ore. Last year at this...
AVR, aortic valve replacement, middle-aged patients, University of Sydney study, metal, tissue
News | Heart Valve Repair| January 15, 2016
Patients between the ages of 40 and 70 who undergo aortic valve replacement (AVR) may fare better with tissue-based...
CardioKinetix, Parachute device, heart failure, PARACHUTE IV trial, half enrollment
News | Heart Failure| January 15, 2016
CardioKinetix Inc. announced that it has enrolled more than half of the subjects in its pivotal United States trial,...
Sapien III, Sapien 3, PARTNER III

The Edwards Sapien 3 valve uses a skirt at its base to prevent paravalvular leak. This is the newest version of the Sapien and will be used in the upcoming PARTNER III Trial.

Feature | Heart Valve Repair| January 15, 2016 | Dave Fornell
January 15, 2016 — The U.S.
heart valve formation, newborns, congenital heart defects, Cornell study
News | Congenital Heart| January 14, 2016
January 14, 2016 — Cornell biomedical engineers have discovered natural triggers that could reduce the chance of life
Overlay Init